Tuesday, July 5, 2011

Eli Lilly Reaffirms Commitment to Innovation but Needs to Deliver

EP Vantage submits:

Reaffirming that it remains one of the staunchest advocates of innovation over diversification, Eli Lilly?s (LLY) strategy update yesterday contained few surprises. The company reiterated its intention to continue investing in its pipeline to deliver fresh growth post-patent cliff, and explicitly ruled out moves into new areas like generics or any attempt to buy its way out of trouble with a big buck acquisition.

Big pharma?s productivity problems have prompted a variety of strategic moves and Lilly, along with Bristol-Myers Squibb (BMY) and AstraZeneca (AZN), has largely resisted pressure to add more reliable and less risky revenue generators. The next couple of years will contain crucial tests of conviction as they all attempt to deliver on pipeline promises ? the analysis below suggests investors are still largely declining to bet on success.

Growth engines

Lilly has not completely shunned more stable revenue generators and has invested in what it terms

Complete Story »

Mandy Moore Shannon Elizabeth Maggie Gyllenhaal Foxy Brown Ivana Bozilovic

No comments:

Post a Comment